Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge
-
Published:2024-07-19
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Malouli Daniel, Tiwary Meenakshi, Gilbride Roxanne M., Morrow David W.ORCID, Hughes Colette M., Selseth AndreaORCID, Penney Toni, Castanha Priscila, Wallace Megan, Yeung Yulia, Midgett Morgan, Williams Connor, Reed Jason, Yu Yun, Gao LinaORCID, Yun Gabin, Treaster Luke, Laughlin AmandaORCID, Lundy Jeneveve, Tisoncik-Go JenniferORCID, Whitmore Leanne S.ORCID, Aye Pyone P.ORCID, Schiro Faith, Dufour Jason P., Papen Courtney R., Taher Husam, Picker Louis J., Früh KlausORCID, Gale MichaelORCID, Maness Nicholas J.ORCID, Hansen Scott G., Barratt-Boyes SimonORCID, Reed Douglas S.ORCID, Sacha Jonah B.ORCID
Abstract
AbstractAn influenza vaccine approach that overcomes the problem of viral sequence diversity and provides long-lived heterosubtypic protection is urgently needed to protect against pandemic influenza viruses. Here, to determine if lung-resident effector memory T cells induced by cytomegalovirus (CMV)-vectored vaccines expressing conserved internal influenza antigens could protect against lethal influenza challenge, we immunize Mauritian cynomolgus macaques (MCM) with cynomolgus CMV (CyCMV) vaccines expressing H1N1 1918 influenza M1, NP, and PB1 antigens (CyCMV/Flu), and challenge with heterologous, aerosolized avian H5N1 influenza. All six unvaccinated MCM died by seven days post infection with acute respiratory distress, while 54.5% (6/11) CyCMV/Flu-vaccinated MCM survived. Survival correlates with the magnitude of lung-resident influenza-specific CD4 + T cells prior to challenge. These data demonstrate that CD4 + T cells targeting conserved internal influenza proteins can protect against highly pathogenic heterologous influenza challenge and support further exploration of effector memory T cell-based vaccines for universal influenza vaccine development.
Funder
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Reference74 articles.
1. Tenforde, M. W. et al. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. Clin. Infect. Dis. 73, e4244–e4250 (2021). 2. Martins, J. P., Santos, M., Martins, A., Felgueiras, M. & Santos, R. Seasonal Influenza Vaccine Effectiveness in Persons Aged 15-64 Years: A Systematic Review and Meta-Analysis. Vaccines (Basel) 11, 1322 (2023). 3. Organization, W. H. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2023, 14 July 2023. https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a. 4. CDC. Current Bird Flu Situation in Wild Birds. https://www.cdc.gov/flu/avianflu/wildbirds.htm. 5. Imai, M. et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420–428 (2012).
|
|